Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-07-22

FDA Approved: MOVANTIK — Supplemental Application (RedHill Biopharma Ltd)

View source ↗

Summary

The FDA approved a supplemental application for MOVANTIK (naloxegol oxalate) from RedHill Biopharma Ltd, potentially expanding or updating the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • MOVANTIK (Naloxegol oxalate)

Snippet

SUPPL AP for MOVANTIK (NALOXEGOL OXALATE)